Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin patent extension

Executive Summary

Senate Health Committee Chairman Jeffords (R-Vt.) allows investigation of "pipeline drug" regulatory review delays to move forward at the General Accounting Office. GAO is in the process of reviewing whether FDA held up review of certain drugs, including Schering-Plough's Claritin, resulting in the loss of patent exclusivity time as the sponsors have argued. The report was requested by Sen. Leahy (D-Vt.) and other Democrats to examine whether the delays were caused by the sponsors themselves. GAO could not access FDA approval records without the authority of a committee chairman with jurisdiction (1"The Pink Sheet" Nov. 15, 1999, p. 10)

You may also be interested in...



Gore Pro-Generic Campaign Platform Includes Citizen Petition Restrictions

Vice President Gore is promising to address the potential for the FDA citizen petition process to be used to delay generic drug approvals if he is elected President.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel